ORAMED PHARMACEUTICALS INC (ORMP) Stock Price, Quote, News and Overview
NASDAQ:ORMP - Nasdaq - US68403P2039 - Common Stock - Currency: USD
ORMP Quote, Performance and Key Statistics
2.24
-0.01 (-0.44%)
The current stock price of ORMP is 2.24 USD. In the past month the price increased by 5.63%. In the past year, price decreased by -6.05%.
ORMP Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 54.91 | 716.27B | ||
| JNJ | JOHNSON & JOHNSON | 15.34 | 370.87B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 19.47 | 300.70B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.11 | 215.19B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 18.53 | 213.77B | ||
| MRK | MERCK & CO. INC. | 10.32 | 202.39B | ||
| PFE | PFIZER INC | 7.19 | 130.95B | ||
| SNY | SANOFI-ADR | 13.4 | 125.00B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.56 | 98.05B | ||
| GSK | GSK PLC-SPON ADR | 6.86 | 75.61B | ||
| ZTS | ZOETIS INC | 26.9 | 72.23B | ||
| HLN | HALEON PLC-ADR | 22.31 | 48.29B |
Related stock screener links
About ORMP
Company Profile
Oramed Pharmaceuticals, Inc. engages in the provision of oral delivery solutions for drugs delivered via injection. The company is headquartered in New York City, New York and currently employs 13 full-time employees. The company went IPO on 2002-04-01. The firm has developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its Protein Oral Delivery (POD) technology is designed to protect drug integrity and increase absorption. Its pipeline includes ORMD-0801 (Oral Insulin) Diabetes, ORMD-0801 (Oral Insulin) NASH, and ORMD 0901 (Oral GLP-1). Its oral insulin (ORMD-0801) has the potential to create a new paradigm in the treatment of diabetes through oral delivery of insulin at an earlier stage of treatment. Its oral insulin capsule (ORMD-0801) has shown a reduction of liver fat content in early clinical trials. The company is also developing an oral Glucagon-like peptide-1 (GLP-1) analog capsule (ORMD-0901), which is an incretin hormone that stimulates the secretion of insulin from the pancreas.
Company Info
ORAMED PHARMACEUTICALS INC
1185 Avenue Of The Americas, 3Rd Floor
New York City NEW YORK 10036 US
CEO: Nadav Kidron
Employees: 13
Phone: 16468441164
ORAMED PHARMACEUTICALS INC / ORMP FAQ
What is the stock price of ORAMED PHARMACEUTICALS INC today?
The current stock price of ORMP is 2.24 USD. The price decreased by -0.44% in the last trading session.
What is the ticker symbol for ORAMED PHARMACEUTICALS INC stock?
The exchange symbol of ORAMED PHARMACEUTICALS INC is ORMP and it is listed on the Nasdaq exchange.
On which exchange is ORMP stock listed?
ORMP stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ORAMED PHARMACEUTICALS INC stock?
6 analysts have analysed ORMP and the average price target is 3.32 USD. This implies a price increase of 47.99% is expected in the next year compared to the current price of 2.24. Check the ORAMED PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ORAMED PHARMACEUTICALS INC worth?
ORAMED PHARMACEUTICALS INC (ORMP) has a market capitalization of 91.50M USD. This makes ORMP a Micro Cap stock.
How many employees does ORAMED PHARMACEUTICALS INC have?
ORAMED PHARMACEUTICALS INC (ORMP) currently has 13 employees.
What are the support and resistance levels for ORAMED PHARMACEUTICALS INC (ORMP) stock?
ORAMED PHARMACEUTICALS INC (ORMP) has a support level at 2.13 and a resistance level at 2.26. Check the full technical report for a detailed analysis of ORMP support and resistance levels.
Should I buy ORAMED PHARMACEUTICALS INC (ORMP) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ORMP, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ORMP, evaluating the profitability, health, valuation and growth aspects
- ORAMED PHARMACEUTICALS INC (ORMP) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ORAMED PHARMACEUTICALS INC (ORMP) Sales and EPS estimates to see what analysts future expectations are.
- ORAMED PHARMACEUTICALS INC (ORMP) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ORAMED PHARMACEUTICALS INC (ORMP) Insider and Institutional Ownership to learn about the owners and their transactions.
- ORAMED PHARMACEUTICALS INC (ORMP) Stock Chart to make your own analysis
- ORAMED PHARMACEUTICALS INC (ORMP) Latest news and press-releases to stay up to date.
Does ORAMED PHARMACEUTICALS INC (ORMP) stock pay dividends?
ORMP does not pay a dividend.
When does ORAMED PHARMACEUTICALS INC (ORMP) report earnings?
ORAMED PHARMACEUTICALS INC (ORMP) will report earnings on 2025-08-12.
What is the Price/Earnings (PE) ratio of ORAMED PHARMACEUTICALS INC (ORMP)?
ORAMED PHARMACEUTICALS INC (ORMP) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.18).
What is the Short Interest ratio of ORAMED PHARMACEUTICALS INC (ORMP) stock?
The outstanding short interest for ORAMED PHARMACEUTICALS INC (ORMP) is 2.04% of its float. Check the ownership tab for more information on the ORMP short interest.
ORMP Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to ORMP. When comparing the yearly performance of all stocks, ORMP turns out to be only a medium performer in the overall market: it outperformed 50.88% of all stocks.
ORMP Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ORMP. ORMP has a great financial health rating, but its profitability evaluates not so good.
ORMP Financial Highlights
Over the last trailing twelve months ORMP reported a non-GAAP Earnings per Share(EPS) of -0.18. The EPS decreased by -228.57% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -12.27% | ||
| ROE | -13.03% | ||
| Debt/Equity | 0 |
ORMP Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 43% to ORMP. The Buy consensus is the average rating of analysts ratings from 6 analysts.